Novacea files $75M IPO
South San Francisco-based Novacea has filed an IPO designed to raise $75 million. Novacea is developing cancer therapies. No details on the number of shares to be offered or the price per share were revealed. Novacea lost $16.9 million in the first nine months of 2005.
- read this AP report for more
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
